Long Wall is a Long Beach, California defense manufacturer building cost-effective, mass-producible missile defense systems. Founded in 2017 as the rocket startup ABL Space Systems, it rebranded to Long Wall in February 2025 and pivoted from commercial satellite launch to defense, repurposing years of launch-vehicle engineering into interceptors, target rockets, and deployable ground infrastructure. Its lineup includes Cyclops, a surface-launched exoatmospheric interceptor; RSX, a low-cost liquid booster for flight testing and threat replication; and Ironwood, rapidly deployable ground support equipment. The company's thesis is that modern threats - hypersonic weapons, growing nuclear arsenals, and raid sizes in the hundreds - have outrun the price and production volume of legacy interceptors, so defense needs magazine depth measured in thousands, not dozens.
Mark Gaffney is the Chief Executive Officer and Board member of Calluna Pharma, an Oslo-based clinical-stage biopharma chasing inflammatory and fibrotic disease by tuning the body's innate immune system. A mechanical engineer turned lawyer turned dealmaker, he spent two decades building and selling biotechs - Oxular went to Regeneron, Vedere Bio to Novartis - before taking the helm of a company born from the merger of Oxitope Pharma and Arxx Therapeutics and freshly backed by a 75 million euro Series A.